Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Scientists want to find out if using three different treatments together can make cancer treatment better for patients who have a specific type of myeloma that has come back after treatment.
Scientists want to find out if using three different treatments together can make cancer treatment better for patients who have a specific type of myeloma that has come back after treatment.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).
The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: